What is FlowMetric?
FlowMetric operates within the Precision Medicine sector, offering comprehensive Flow Cytometry Solutions through its family of companies. As a contract research organization, FlowMetric provides critical services for global partners across various therapeutic areas and all phases of pharmaceutical development, from preclinical research to clinical trials (Phase 0-IV). Headquartered in Doylestown, Pennsylvania, the company's expertise spans both non-GLP and GLP toxicology studies, positioning it as a key player in advancing drug discovery and development.
How much funding has FlowMetric raised?
FlowMetric has raised a total of $2.1M across 3 funding rounds:
Private Equity
$926K
Private Equity
$820K
Debt
$350K
Private Equity (2015): $926K, investors not publicly disclosed
Private Equity (2017): $820K, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Key Investors in FlowMetric
PPP
Public-Private Partnership
What's next for FlowMetric?
The substantial enterprise-level funding suggests FlowMetric is poised for significant expansion and further integration of its advanced flow cytometry and cell sorting capabilities. This capital injection is likely to fuel research and development initiatives, enhance operational capacity, and potentially broaden its market reach. The company's strategic positioning in precision medicine, coupled with its comprehensive service offerings, indicates a strong potential for future growth and innovation in the biopharmaceutical landscape.
See full FlowMetric company page
